Focusing on the CDMO business for new modalities in addition to new drug development
The Fujifilm Group's healthcare business is engaged in a wide range of areas, encompassing prevention, diagnosis, and treatment as a total healthcare company. FUJIFILM Toyama Chemical, one of the core companies in the healthcare segment, is committed to solving social issues through its pharmaceutical business.
Leveraging over 40 years of expertise in anti-infective drugs, we have recently focused on contract manufacturing as the only company capable of manufacturing sterile penicillin antibiotics products in Japan.
In addition, we are advancing our CDMO*1 business for formulations using lipid nanoparticle (LNP), liposome, and other drug delivery system (DDS) technologies, which are also used in the mRNA vaccines for COVID-19. A new formulation manufacturing facility capable of producing commercial products became operational in 2020. Going forward, we will expand the CDMO business, including new modalities such as LNP, to meet customer needs.
- *1 CDMO stands for Contract Development and Manufacturing Organization.
Main Business Fields
We are promoting the development of drugs for drug-resistant bacteria, so-called “silent pandemics,” and for diseases caused by highly lethal and virulent viruses.
As the only manufacturer in Japan capable of synthesizing penicillin antibiotics and producing sterile products, we also engage in contract manufacturing.
We deploy an integrated CDMO business from the design to process development and commercial production of formulations using LNP and liposomes, which are DDS technologies, by leveraging Fujifilm’s advanced nano dispersion, analysis, and synthesis technologies cultivated and evolved through the development of a wide range of products including photographic films, as well as our production expertise and manufacturing facilities.
We undertake contract manufacturing of LNP and liposome formulations for clinical trials with Japan’s first commercial compatible at its LNP/liposome production facility located in Toyama City, Japan.
In addition, we plan to build a new bio-CDMO site in Toyama City with the goal of starting operations in fiscal year ending March 2027. In cooperation with FUJIFILM Diosynth Biotechnologies, a Fujifilm Group company with more than 30 years of experience as a bio-CDMO that can offer a comprehensive list of services, we will provide process development and manufacturing services for biopharmaceuticals.
Discovery support CRO Business
Fujifilm will expand a Japan-based "discovery support CRO business" to support drug research and development conducted by pharmaceutical companies, bio-ventures, academia, and others with the combined resources of Fujifilm Group.
FUJIFILM Toyama Chemical will leverage its advanced manufacturing facilities and long-standing expertise in drug discovery to provide services to its customers.